Your Health, We Care
Release date: 2024-08-13 15:19:55 Recommended: 130
Pemigatinib is a small molecule kinase inhibitor targeting the fibroblast growth factor receptor (FGFR), primarily for the treatment of advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.
The recommended dose of Pemigatinib varies depending on the patient's specific situation, but in general, the recommended dose of Pemigatinib for cholangiocarcinoma patients is usually 13.5 mg orally once daily for 14 days, followed by 7 days off in the next 21-day cycle. This cycle is repeated until the disease progresses or the patient experiences unacceptable toxicity. This balances the efficacy of the drug with the patient's tolerability.
The above dosage recommendations are only for the reference of patients and their families, and the specific dosage should be determined by patients under the guidance of doctors and the specific conditions of patients.
The use of Pemigatinib in specific patients requires special caution and is tailored to the specific situation of the patient. Patients should consult their doctor before use and follow their doctor's instructions for treatment.
In patients with severe hepatic impairment (eg, total bilirubin > 3×ULN with any elevated AST), the recommended dose of Pemigatinib may be reduced to 9 mg and the treatment regimen (intermittent or continuous) is specified according to the indication.
Dose adjustment is generally not recommended in patients with mild or moderate hepatic impairment (eg, total bilirubin between the upper limit of normal and 1.5×ULN, or elevated AST without other indicators of severe hepatic impairment), but patients should be closely monitored for liver function and drug response.
Breastfeeding women should not breastfeed while taking Pemigatinib and for 1 week after the last dose.
The specific circumstances of different patients vary from person to person, and care for patients should be individualized when it comes to caring for them.
Different patients have different psychological needs and responses, and medical staff should develop a personalized psychological care plan according to the specific situation of the patient.
During the treatment process, we should continue to pay attention to the psychological changes of the patients, identify the problems in time and intervene to ensure that the patients always maintain a positive attitude and a good psychological state.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
